4/A: Charles River Labs Executive William Barbo Reports Stock Transactions Following Performance Goal Achievement

Corporate Executive VP & CCO William D. Barbo reports acquisition and disposal of Charles River Laboratories International, Inc. stock following the achievement of performance goals.

Summary

• William D. Barbo, Corporate Executive VP & CCO of Charles River Laboratories International, Inc., filed an amendment to a Form 4 regarding changes in beneficial ownership.
• The report details transactions that occurred on January 29, 2024, and were originally filed on January 31, 2024.
• Barbo acquired 2,934 shares of common stock following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021.
• Barbo also disposed of 744 shares of common stock at a price of $220.28.
• Following these transactions, Barbo directly owns 11,293 shares and indirectly owns 19,634 shares through a trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The stock transactions are part of a standard compensation plan. The acquisition of shares due to performance goals is a positive sign, but the disposal of some shares tempers the overall sentiment.

Positives

• The acquisition of shares reflects the achievement of performance goals, which could be seen as a positive indicator of company performance.

Negatives

• The disposal of 744 shares by the executive could be interpreted negatively by some investors, although the amount is relatively small.

Risks

• Executive stock transactions can sometimes be misinterpreted by the market, leading to short-term price volatility.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often related to compensation packages and performance incentives. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation structures, including performance-based equity awards, are standard practice among publicly traded companies like Charles River Laboratories.
• Companies such as Laboratory Corporation of America Holdings (LH) and Quest Diagnostics (DGX) also utilize similar equity-based compensation plans for their executives.
• The specific details of these plans, such as performance metrics and vesting schedules, can vary significantly between companies.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholders due to the change in ownership, but the overall effect is likely to be minimal.

Key Dates